It’s Their Own Fault We No Longer Default to Respect
There Was a Horrific School Shooting in Canada...and Their Police Used a Weird...
Person of Interest Arrested in Connection to the Abduction of Nancy Guthrie
Fraud Nation
Technological Sweet Spot
Public Opinion: A Tyrant Against Hard Decisions
Peggy Noonan Loses Her Noodle Over Washington Post Layoffs
Misconduct Rampant: America’s Leaders Increasingly Prioritize Agendas Over Fairness, Laws
Pass the SAVE America Act
Trump's DOJ Seeks Justice for Victims of Benghazi
2026 Olympics: Let’s Talk About Crotch Scandals
The Washington Post Is Paying the Bill for Free Speech
Republicans Siding With Big Banks in Stablecoin Fight Could Tank Trump’s Affordability Age...
Freezing Deaths, Garbage Piles in Largest Sanctuary City
Woke DC Grand Jury Denies Indictments of Six Democrats Accused of Sedition
Tipsheet

Rep. Maloney: Republicans Would Reject Cancer Cure

On top of being terrorists and hostage takers, Democrat Rep. Carolyn Maloney apparently thinks Republicans hate cancer patients  because they wouldn't budge on tax hikes during the debt debate.

Advertisement

"If President Obama came in with a cure for cancer they would have turned that down, too," she said.

FLASHBACK: Rationing for cancer patients begins through ObamaCare.

A decision to rescind endorsement of the drug would reignite the highly charged debate over US health care reform and how much the state should spend on new and expensive treatments.

Avastin, the world’s best selling cancer drug, is primarily used to treat colon cancer and was approved by the US Food and Drug Administration in 2008 for use on women with breast cancer that has spread.

It costs $8,000 (£5,000) a month and is given to about 17,500 women in the US a year. The drug was initially approved after a study found that, by preventing blood flow to tumours, it extended the amount of time until the disease worsened by more than five months. However, two new studies have shown that the drug may not even extend life by an extra month.

The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited "effectiveness" grounds for the decision. But it has been claimed that "cost effectiveness" was the real reason ahead of reforms in which the government will extend health insurance to the poorest.

 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement